Navigation Links
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
Date:6/11/2008

ious infections, malignancies, heart failure, central nervous system disorders, reactivation of hepatitis B, and other serious events.

About Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic and debilitating disease that affects approximately 1.3 million people in the United States and more than three million people in Europe. Signs and symptoms of RA include pain, stiffness and motion restriction in multiple joints. Because RA is a progressive disease, it can cause permanent joint deformity and severe disability if not diagnosed early or if initial treatment is delayed. RA can occur at any age, but is most common in adults 30-50 years old and is two-to-three times more prevalent in women than in men. The cause of RA is unknown, although genetic factors may contribute to the disease.

About Golimumab

Golimumab, Centocor Inc.'s and Schering-Plough Corporation's next-generation human anti-TNF-alpha monoclonal antibody, is currently in the most comprehensive Phase 3 development program to date for an anti-TNF-alpha biologic therapy. With ongoing studies for the treatment of RA, psoriatic arthritis and ankylosing spondylitis, golimumab is being studied as an every four-week subcutaneous injection and an IV infusion therapy. Golimumab targets and neutralizes both the soluble and membrane-bound forms of TNF-alpha.

Centocor discovered golimumab and has exclusive marketing rights to the product in the United States. Pending regulatory approval, Schering-Plough will assume exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan where golimumab will be co-marketed by Mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where golimumab will be exclusively marketed by Janssen-Cilag; and China where golimumab will be exclusively marketed by Xian-Janssen.

About Centocor

Centocor is harnessing the power of world-leading research and biomanufacturing
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... 2014   Royal Philips  (NYSE: PHG, AEX: PHIA) ... new ultrasound system designed to enable global hospitals and ... volumes and cost pressures. Making its debut at the  ... Barcelona this week, Affiniti provides innovative ... fewer resources deliver high quality patient care. ...
(Date:8/29/2014)... , Aug. 29, 2014 The Competitive ... regulatory and marketplace changes. CI leaders who adjust will ... In a new Best Practices, LLC study CI ... actionable insights, including: - Use secondary research ... primary research - Internal staff who are ...
(Date:8/29/2014)... Aug. 29, 2014   Mast Therapeutics, Inc. ... announced today that Santosh Vetticaden, Chief Medical Officer ... Company, for personal reasons, in mid-September.  Edwin ... of Aires Pharmaceuticals, which Mast acquired earlier this ... the Company,s interim Chief Medical Officer.  Dr. Parsley ...
Breaking Medicine Technology:Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4
... 19 According to Millennium Research Group (MRG), the ... instituted under the Patient Protection and Affordable Care Act ... colorectal cancer screening for a large segment of the ... reimbursement, a growing number of colorectal cancer screening procedures ...
... Aug. 19 Boston Scientific Corporation (NYSE: ... studies involving the Company,s Women,s Health products will ... the International Continence Society (ICS) and International Urogynecological ... pelvic floor reconstruction systems and mid-urethral sling systems. ...
Cached Medicine Technology:New Colorectal Cancer Screening Coverage to Drive US Gastrointestinal Endoscopy Device Market to Almost $2.2 Billion by 2014 2New Colorectal Cancer Screening Coverage to Drive US Gastrointestinal Endoscopy Device Market to Almost $2.2 Billion by 2014 3Boston Scientific's Women's Health Products Featured in Studies at the Joint Annual Meeting of the International Continence Society and International Urogynecological Association 2Boston Scientific's Women's Health Products Featured in Studies at the Joint Annual Meeting of the International Continence Society and International Urogynecological Association 3Boston Scientific's Women's Health Products Featured in Studies at the Joint Annual Meeting of the International Continence Society and International Urogynecological Association 4Boston Scientific's Women's Health Products Featured in Studies at the Joint Annual Meeting of the International Continence Society and International Urogynecological Association 5
(Date:9/1/2014)... -- Watching action shows on TV may be bad for ... more snack food while watching action films and programs than ... "We find that if you,re watching an action movie while ... Aner Tal, of the Cornell Food and Brand Lab, said ... distracting the program is, the more you will eat." ...
(Date:9/1/2014)... 01, 2014 More than 200 Lipitor ... a federal litigation that continues to progress in the ... LLP reports. , A federal Case List published ... the widely-used cholesterol medication by plaintiffs who developed Type ... claims, Pfizer Inc. failed to adequately warn patients and ...
(Date:9/1/2014)... Spain Monday 1 September 2014: Daily fruit consumption ... to 40%, according to research presented at ESC Congress ... findings from the seven year follow-up study of nearly ... that the more fruit people ate, the more their ... including ischaemic heart disease (IHD) and stroke, is the ...
(Date:9/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... AND GLOBAL MARKETS , the global market for blood-brain ... is expected to reach $38.7 million in 2014. This ... 2019, which is equivalent to 64.9% compound annual growth ... (RMT) segment is forecasted to grow at a CAGR ...
(Date:9/1/2014)... Secaucus, NJ (PRWEB) September 01, 2014 Registration ... For The Warriors® 5K and 1-Mile Race to be held ... at The Plaza Court Yard at Harmon Meadow in Secaucus, ... For The Warriors®, a national nonprofit dedicated to restoring a ... for our service members and our military families. , General ...
Breaking Medicine News(10 mins):Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2
... shared responsibility to a whole new level. Six ... $2 trillion in healthcare costs over the next decade. ... within our grasp.Blue Shield of California has long advocated ... are pleased that these groups are embracing the challenge ...
... 11, 2009 Iron chelating drugs have been heavily ... a form of blood cancer often treated with blood ... the body, are highly expensive and potentially toxic. A ... finds that their increased use has been propagated ...
... 11 Stephen J. Ubl, president and CEO of ... statement regarding today,s White House announcement of an industry ... are very pleased to join with President Obama and ... improving access to affordable, quality health care. As ...
... -- Jiangbo,Pharmaceuticals, Inc. (OTC Bulletin Board: GNPH) (the "Company"), ... People,s Republic,of China, today announced that its stock will ... the new ticker symbol "JGBO" as of May 12, ... symbol "GNPH" at the,end of May 11, 2009. , ...
... BlueCross BlueShield Give 40 in District Opportunity to Help Community Prevent HIV/AIDS ... ... and Education ( SHIRE ), Inc., is reaching out to 40 young ... help prevent the spread of HIV and AIDS and childhood obesity. ...
... Medical TechnologyWASHINGTON, May 11 Patients from across the ... about how medical technology has helped improve or save ... House of Representatives Energy & Commerce Committee hearing on ... repeal the Food and Drug Administration,s (FDA) preemption authority. ...
Cached Medicine News:Health News:AdvaMed Pleased to Work with the White House to Advance Health Reform 2Health News:Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP 2Health News:Stepping Up: D.C. Wards 7 and 8 Teens to Teach Prevention of HIV, Obesity in Summer Youth Program 2Health News:Stepping Up: D.C. Wards 7 and 8 Teens to Teach Prevention of HIV, Obesity in Summer Youth Program 3Health News:Stepping Up: D.C. Wards 7 and 8 Teens to Teach Prevention of HIV, Obesity in Summer Youth Program 4Health News:Patients Call for Continued FDA Preemption Authority 2Health News:Patients Call for Continued FDA Preemption Authority 3Health News:Patients Call for Continued FDA Preemption Authority 4
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed....
... Timesh 1.6 Titanium Cranial Fixation Systems ... benefits specifically requested by surgeons and ... cranioplasty implants may be either shaped ... procedure warrants, a pre-measured, cut, bent ...
... LeibingerTitanium Microplus System is a ... skeletal fixation armamentarium. It may ... vault, nasal, zygomatic and orbital ... especially where increased strength over ...
... Codman Sofwire Cable ... bony fixation including sublaminar ... maxillo facial surgery, sternotomy ... cables and a complete ...
Medicine Products: